Literature DB >> 31343993

Simplified Molecular Subtyping of Medulloblastoma for Reduced Cost and Improved Turnaround Time.

Somruetai Shuangshoti1, Paveen Tadadontip2, Piti Techavichit3, Paul S Thorner4,5, Shanop Shuangshoti4,6, Chinachote Teerapakpinyo6.   

Abstract

Molecular subtyping of medulloblastoma (MB) has become increasingly important for prognosis and management. Typically this involves detailed molecular genetic testing which may not be available in all centers. The purpose of the present study was to find a simplified approach to assign molecular subtypes of MB for routine use in centers with more limited resources. The molecular subtypes of MBs from 32 Thai patients, aged 0.5 to 35 years, were first determined by NanoString. These results were then compared with those obtained using a combination of limited immunohistochemistry (IHC) (β-catenin, GAB-1, YAP-1, p75-NGFR, OTX2) and CTNNTB exon 3 mutation analysis. By NanoString assay, there were 6 MBs (19%) in the wingless (WNT) group, 8 (25%) in the sonic hedgehog (SHH) group, 7 (22%) in group 3, and 11 (34%) in group 4. Although β-catenin immunostaining missed 4/6 WNT MBs, CTNNTB mutation analysis confirmed all WNT MB cases with amplifiable DNA. The IHC panel correctly assigned all the other molecular subtypes, except for 1 MB in group 4. Thus, our protocol was able to correctly categorized 31/32 cases or 97% of cases. Our study is the first to report molecular subtypes of MB in Southeast Asia. We found that molecular subgroups of MBs can be reliably assigned using a limited IHC panel of β-catenin, GAB-1, YAP-1, p75-NGFR, OTX2, together with CTNNTB exon 3 mutation analysis. This simplified approach incurs lower cost and faster turnaround time compared with more elaborate molecular methodologies and should be beneficial to centers with reduced laboratory resources.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31343993     DOI: 10.1097/PAI.0000000000000794

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  3 in total

1.  Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression.

Authors:  Andrey Korshunov; Konstantin Okonechnikov; Damian Stichel; Daniel Schrimpf; Alberto Delaidelli; Svenja Tonn; Martin Mynarek; Philipp Sievers; Felix Sahm; David T W Jones; Andreas von Deimling; Stefan M Pfister; Marcel Kool
Journal:  Acta Neuropathol       Date:  2022-06-30       Impact factor: 15.887

2.  MRI Radiogenomics of Pediatric Medulloblastoma: A Multicenter Study.

Authors:  Michael Zhang; Samuel W Wong; Jason N Wright; Matthias W Wagner; Sebastian Toescu; Michelle Han; Lydia T Tam; Quan Zhou; Saman S Ahmadian; Katie Shpanskaya; Seth Lummus; Hollie Lai; Azam Eghbal; Alireza Radmanesh; Jordan Nemelka; Stephen Harward; Michael Malinzak; Suzanne Laughlin; Sébastien Perreault; Kristina R M Braun; Robert M Lober; Yoon Jae Cho; Birgit Ertl-Wagner; Chang Y Ho; Kshitij Mankad; Hannes Vogel; Samuel H Cheshier; Thomas S Jacques; Kristian Aquilina; Paul G Fisher; Michael Taylor; Tina Poussaint; Nicholas A Vitanza; Gerald A Grant; Stefan Pfister; Eric Thompson; Alok Jaju; Vijay Ramaswamy; Kristen W Yeom
Journal:  Radiology       Date:  2022-04-19       Impact factor: 29.146

3.  Assessing the utility and attitudes toward molecular testing in neuro-oncology: a survey of the Society for Neuro-Oncology members.

Authors:  Shannon Fortin Ensign; Maya Hrachova; Susan Chang; Maciej M Mrugala
Journal:  Neurooncol Pract       Date:  2021-02-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.